Coronavirus in Argentina: 38 deaths and 5,076 infections confirmed in the last 24 hours

With these data, the cumulative total number of cases since the beginning of the pandemic is 8,981,155, while deaths total 127,295

Guardar
IMAGEN DE ARCHIVO. Trabajadores de la Salud en un centro de pruebas para el COVID-19, en Buenos Aires, Argentina. Enero 6, 2022. REUTERS/Agustin Marcarian
IMAGEN DE ARCHIVO. Trabajadores de la Salud en un centro de pruebas para el COVID-19, en Buenos Aires, Argentina. Enero 6, 2022. REUTERS/Agustin Marcarian

The Ministry of Health of the Nation reported this Tuesday, March 15, 2022 that, in the last 24 hours, 38 deaths from coronavirus and 5,076 new infections were recorded. With these data, the cumulative total number of cases since the beginning of the pandemic is 8,981,155, while deaths total 127,295.

Amid a sharp and sustained decline in cases across the country, yesterday the province of Tierra del Fuego again reduced new coronavirus infections to less than half within a week. At the moment there are only 32 active cases left in the jurisdiction.

According to an official report by the provincial Ministry of Health, between March 6 and 12, 14 new cases were diagnosed, compared to 40 the previous week, from February 27 to March 5. In turn, the number of infections fell to one-sixth in the previous week from 20 to 26 February, when it went from 239 to 40.

The survey also mentions that in the last week there was a single hospitalization for coronavirus in the intensive care unit (ITU) of the Regional Hospital of the city of Rio Grande. On the other hand, there are no internships in general wards in both cities, nor in intensive care in the city of Ushuaia.

Meanwhile, there were two deaths, totaling 545 people who died from the virus since the start of the pandemic.

Yesterday, Monday, March 14, the positivity rate recorded was 12.38%, a figure close to 10% recommended by WHO (EFE/Juan Ignacio Roncoroni)

The report specifies that in the “tenth epidemiological week of 2022″, 8 infections were detected in the city of Ushuaia, 6 in the city of Rio Grande and none in the municipality of Tolhuin. This totals 44,969 cases in the jurisdiction since March 2020, of which 44,392 were discharged and 32 remain active, most of them as a result of having contracted the disease through “community transmission or close contact”.

Regarding the National Vaccination Plan, the Ministry of Health in Fueguino explained that the province has received, so far, 394,493 doses of vaccines, of which 358,151 have been applied. A total of 156,962 people received the first dose and 144,212 completed the schedule with the second application. In addition, 8,595 additional doses, 256 single-use vaccines and 48,126 booster doses were applied, according to data from the Public Vaccination Monitor.

The Minister of Health, Judith Do Giglio, said in statements to the local media that “not only the demand for swabbing people but also the viral circulation, that is, the number of sick people, has fallen.”

To date, the total number of inoculations applied in the country is 95,170,353, of which 40,513,389 correspond to the first dose, 36,702,446 to the second dose (EFE/Juan Ignacio Roncoroni/Archive)

On the other hand, nationally and since the beginning of the vaccination campaign, Argentina received more than 112 million vaccines against COVID-19. Of that total, 102,683,890 were sent to the provinces and 5,083,000 were donated to other countries. According to the latest official data, until the last update, the total number of inoculations applied amounts to 95,170,353, of which 40,513,389 correspond to the first dose, 36,702,446 to the second, 3,038,520 were additional and another 14,915,998 were booster doses.

In recent days, the Ministry of Health has authorized the application of the Moderna vaccine for children aged 6 to 11 years, thus adding to that of Sinopharm and Pfizer among those who have the guarantee to be applied to that age group.

In a statement, the portfolio led by Carla Vizzotti specified that the decision is based on the analysis carried out by the National Institute of Medicines based on the clinical evidence that demonstrates the feasibility of its application.

KEEP READING:

Guardar